|
|
Blood, 15 November 2003, Vol. 102, No. 10, pp. 3759-3764.
Prepublished online as a Blood First Edition Paper on July 24, 2003; DOI 10.1182/blood-2003-03-0801.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
Robert A. Kyle,
Terry M. Therneau,
S. Vincent Rajkumar,
Ellen D. Remstein,
Janice R. Offord,
Dirk R. Larson,
Matthew F. Plevak, and
L. Joseph Melton, III
From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Division of Biostatistics (T.M.T, J.R.O., D.R.L., M.F.P.), the Division of Anatomic Pathology (E.D.R.), and the Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN.
Little effort has been made to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS) of the immunoglobulin M (IgM) class, which progresses to lymphoma or Waldenström macroglobulinemia, whereas IgA and IgG MGUS progress to multiple myeloma, primary amyloidosis (AL), or a related plasma cell disorder. From 1960 to 1994, IgM MGUS was diagnosed in 213 patients in southeastern Minnesota. The end point was progression to lymphoma or a related disorder, as assessed with the Kaplan-Meier method. The 213 patients were followed up for 1567 person-years (median, 6.3 years per patient). Lymphoma developed in 17 patients (relative risk [RR], 14.8), Waldenström macroglobulinemia in 6 (RR, 262), primary amyloidosis in 3 (RR, 16.3), and chronic lymphocytic leukemia in 3 (RR, 5.7). The relative risk of progression was 16-fold higher in the patients with IgM MGUS than in the white population of the Iowa Surveillance, Epidemiology, and End Results Program. Cumulative incidence of progression was 10% at 5 years, 18% at 10 years, and 24% at 15 years. On multivariate analysis, the serum monoclonal protein and serum albumin concentrations at diagnosis were the only risk factors for progression to lymphoma or a related disorder. Risk for progression to lymphoma or a related disorder at 10 years after the diagnosis of MGUS was 14% with an initial monoclonal protein concentration of 0.5 g/dL or less, 26% with 1.5 g/dL, 34% for 2.0 g/dL, and 41% for more than 2.5 g/dL. (Blood. 2003;102:3759-3764)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Koshiol, G. Gridley, E. A. Engels, M. L. McMaster, and O. Landgren
Chronic Immune Stimulation and Subsequent Waldenstrom Macroglobulinemia
Arch Intern Med,
September 22, 2008;
168(17):
1903 - 1909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. McMaster, G. Csako, T. R. Giambarresi, L. Vasquez, M. Berg, S. Saddlemire, B. Hulley, and M. A. Tucker
Long-term Evaluation of Three Multiple-Case Waldenstrom Macroglobulinemia Families
Clin. Cancer Res.,
September 1, 2007;
13(17):
5063 - 5069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hatjiharissi, H. Ngo, A. A. Leontovich, X. Leleu, M. Timm, M. Melhem, D. George, G. Lu, J. Ghobrial, Y. Alsayed, et al.
Proteomic Analysis of Waldenstrom Macroglobulinemia
Cancer Res.,
April 15, 2007;
67(8):
3777 - 3784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
298 - 327.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Chng, R. F. Schop, T. Price-Troska, I. Ghobrial, N. Kay, D. F. Jelinek, M. A. Gertz, A. Dispenzieri, M. Lacy, R. A. Kyle, et al.
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Blood,
October 15, 2006;
108(8):
2755 - 2763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kriangkum, B. J. Taylor, E. Strachan, M. J. Mant, T. Reiman, A. R. Belch, and L. M. Pilarski
Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery
Blood,
April 1, 2006;
107(7):
2920 - 2927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Baldini, M. Goldaniga, A. Guffanti, C. Broglia, S. Cortelazzo, A. Rossi, E. Morra, M. Colombi, V. Callea, E. Pogliani, et al.
Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenstrom's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System
J. Clin. Oncol.,
July 20, 2005;
23(21):
4662 - 4668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eurelings, H. M. Lokhorst, S. Kalmijn, J.H.J. Wokke, and N. C. Notermans
Malignant transformation in polyneuropathy associated with monoclonal gammopathy
Neurology,
June 28, 2005;
64(12):
2079 - 2084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, R. A. Kyle, A. Anagnostopoulos, and S. P. Treon
Diagnosis and Management of Waldenstrom's Macroglobulinemia
J. Clin. Oncol.,
March 1, 2005;
23(7):
1564 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Gobbi, L. Baldini, C. Broglia, M. Goldaniga, M. Comelli, P. Morel, E. Morra, S. Cortelazzo, R. Bettini, and G. Merlini
Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance?
Clin. Cancer Res.,
March 1, 2005;
11(5):
1786 - 1790.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
